Wordt geladen...
Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy
As adjuvant chemotherapy (AC) for soft tissue sarcomas is controversial, we performed a retrospective analysis of patients seen at Washington University in St. Louis to evaluate whether it benefited our patient population. Patients were risk-assessed using the Memorial Sloan Kettering Predictive Nom...
Bewaard in:
Hoofdauteurs: | , , , , , |
---|---|
Formaat: | Artigo |
Taal: | Inglês |
Gepubliceerd in: |
BlackWell Publishing Ltd
2014
|
Onderwerpen: | |
Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4101751/ https://ncbi.nlm.nih.gov/pubmed/24574357 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.209 |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|